Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Seres Therapeutics, Inc. MCRB
$5.18
-$0.28 (-5.47%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
697946340.00000000
-
week52high
9.49
-
week52low
2.50
-
Revenue
7128000
-
P/E TTM
-3
-
Beta
2.63183300
-
EPS
-2.48000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 12:30
Описание компании
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| Oppenheimer | Outperform | Outperform | 23 июл 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 23 июл 2021 г. |
| Chardan Capital | Buy | Buy | 23 июл 2021 г. |
| Canaccord Genuity | Buy | Buy | 23 июл 2021 г. |
| Piper Sandler | Overweight | Overweight | 07 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Fraser Claire | A | 48000 | 48000 | 04 янв 2023 г. |
| Ege David S. | D | 46734 | 5012 | 31 окт 2022 г. |
| Ege David S. | A | 51746 | 20000 | 27 окт 2022 г. |
| Arkowitz David | A | 112992 | 42500 | 27 окт 2022 г. |
| Henn Matthew R. | A | 35000 | 35000 | 08 сент 2022 г. |
| Nutritional Health LTP Fund General Partner LLC | A | 5825495 | 5825495 | 05 июл 2022 г. |
| Nutritional Health LTP Fund General Partner LLC | A | 5875711 | 2912748 | 05 июл 2022 г. |
| DesRosier Thomas | A | 104546 | 63492 | 05 июл 2022 г. |
| Henn Matthew R. | A | 47619 | 47619 | 05 июл 2022 г. |
| Arkowitz David | A | 65492 | 63492 | 05 июл 2022 г. |
Новостная лента
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 09:57
Seres Therapeutics (MCRB) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.61 per share a year ago.
Seres Gets FDA Approval And The Share Price Goes Down!
Seeking Alpha
03 мая 2023 г. в 10:29
Biotech investing is a wild ride but share prices falling after FDA approval, as has just happened to Seres Therapeutics VOWST product, is pretty weird. On April 26, Seres achieved FDA approval for VOWST (formerly known as SER-109). This is the first FDA approval for an oral microbiomic product, a big deal for the microbiome.
Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon
The Motley Fool
20 апр 2023 г. в 09:45
Growth stocks fell across the board in 2022. This broad pullback may have created some tremendous buying opportunities.
Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?
Zacks Investment Research
14 апр 2023 г. в 06:51
Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?
Zacks Investment Research
22 мар 2023 г. в 05:21
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.